SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Cheng-long Xie, Wen-Wen Wang, Su-fang Zhang, Jing Gan, Zhen-Guo Liu, Continuous dopaminergic stimulation (CDS)-based treatment in Parkinson's disease patients with motor complications: A systematic review and meta-analysis, Scientific Reports, 2014, 4,

    CrossRef

  2. You have free access to this content2
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  3. 3
    David Salat, Eduardo Tolosa, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  4. 4
    David Salat, Eduardo Tolosa, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  5. 5
    Rebecca Stowe, Natalie Ives, Carl E. Clarke, Kelly Handley, Alexandra Furmston, Katherine Deane, J.J. van Hilten, Keith Wheatley, Richard Gray, Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease, Movement Disorders, 2011, 26, 4
  6. 6
    Santiago Perez-Lloret, Olivier Rascol, Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs Disease, CNS Drugs, 2010, 24, 11, 941

    CrossRef

  7. 7
    Jaime Kulisevsky, Javier Pagonabarraga, Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinsonʼs Disease, Drug Safety, 2010, 33, 2, 147

    CrossRef

  8. 8
    Mitsutoshi Yamamoto, Anthony HV Schapira, Dopamine agonists in Parkinson’s disease, Expert Review of Neurotherapeutics, 2008, 8, 4, 671

    CrossRef

  9. 9
    Anthony H. V. Schapira, C. Warren Olanow, Drug selection and timing of initiation of treatment in early Parkinson's disease, Annals of Neurology, 2008, 64, S2
  10. You have free access to this content10
    M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease, European Journal of Neurology, 2006, 13, 11
  11. 11
    Claudia Ramaker, Willem Johan T. van de Beek, Martijn J. J. Finken, Bob J. J. van Hilten, The efficacy and safety of adjunct bromocriptine therapy for levodopa-induced motor complications: A systematic review, Movement Disorders, 2000, 15, 1
  12. 12
    Yoshikini Mizuno, H. Kowa, T. Nakanishi, N. Yanagisawa, Preliminary Study of B-HT 920, a Novel Dopamine Agonist, for the Treatment of Parkinson’s Disease, Drug Investigation, 1993, 5, 3, 186

    CrossRef

  13. 13
    C Ramaker, d e Beek WJT van, M JJ Finken, van Hilten, Bromocriptine for levodopa-induced motor complications in Parkinson's disease, The Cochrane Library,
  14. 14
    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley, Alex Furmston, Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications, The Cochrane Library,
  15. 15
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Late (Complicated) Parkinson's Disease,